{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:57:08Z","timestamp":1791943028710,"version":"4.3.4"},"reference-count":54,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T00:00:00Z","timestamp":1677974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kungliga Fysiografiska S\u00e4llskapet i Lund (KS, MA, AN)"},{"name":"Crafoord Foundation (JUK)"},{"name":"Magnus Bergvalls Stiftelse (JUK)"},{"name":"Swedish Cancer Society (JUK)"},{"name":"Swedish Childhood Cancer Foundation (JUK)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Therapy resistance remains one of the major challenges for cancer treatment that largely limits treatment benefits and patient survival. The underlying mechanisms that lead to therapy resistance are highly complicated because of the specificity to the cancer subtype and therapy. The expression of the anti-apoptotic protein BCL2 has been shown to be deregulated in T-cell acute lymphoblastic leukemia (T-ALL), where different T-ALL cells display a differential response to the BCL2-specific inhibitor venetoclax. In this study, we observed that the expression of anti-apoptotic BCL2 family genes, such as BCL2, BCL2L1, and MCL1, is highly varied in T-ALL patients, and inhibitors targeting proteins coded by these genes display differential responses in T-ALL cell lines. Three T-ALL cell lines (ALL-SIL, MOLT-16, and LOUCY) were highly sensitive to BCL2 inhibition within a panel of cell lines tested. These cell lines displayed differential BCL2 and BCL2L1 expression. Prolonged exposure to venetoclax led to the development of resistance to it in all three sensitive cell lines. To understand how cells developed venetoclax resistance, we monitored the expression of BCL2, BCL2L1, and MCL1 over the treatment period and compared gene expression between resistant cells and parental sensitive cells. We observed a different trend of regulation in terms of BCL2 family gene expression and global gene expression profile including genes reported to be expressed in cancer stem cells. Gene set enrichment analysis (GSEA) showed enrichment of cytokine signaling in all three cell lines which was supported by the phospho-kinase array where STAT5 phosphorylation was found to be elevated in resistant cells. Collectively, our data suggest that venetoclax resistance can be mediated through the enrichment of distinct gene signatures and cytokine signaling pathways.<\/jats:p>","DOI":"10.3390\/ijms24055004","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T03:49:08Z","timestamp":1678074548000},"page":"5004","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Venetoclax-Resistant T-ALL Cells Display Distinct Cancer Stem Cell Signatures and Enrichment of Cytokine Signaling"],"prefix":"10.3390","volume":"24","author":[{"given":"Kinjal","family":"Shah","sequence":"first","affiliation":[{"name":"Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, 22381 Lund, Sweden"},{"name":"Lund Stem Cell Center, Department of Laboratory Medicine, Lund University, 22184 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Al Ashiri","sequence":"additional","affiliation":[{"name":"Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, 22381 Lund, Sweden"},{"name":"Lund Stem Cell Center, Department of Laboratory Medicine, Lund University, 22184 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Nasimian","sequence":"additional","affiliation":[{"name":"Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, 22381 Lund, Sweden"},{"name":"Lund Stem Cell Center, Department of Laboratory Medicine, Lund University, 22184 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehreen","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, 22381 Lund, Sweden"},{"name":"Lund Stem Cell Center, Department of Laboratory Medicine, Lund University, 22184 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0719-5336","authenticated-orcid":false,"given":"Julhash U.","family":"Kazi","sequence":"additional","affiliation":[{"name":"Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, 22381 Lund, Sweden"},{"name":"Lund Stem Cell Center, Department of Laboratory Medicine, Lund University, 22184 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","article-title":"Pediatric acute lymphoblastic leukemia","volume":"105","author":"Inaba","year":"2020","journal-title":"Haematologica"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bongiovanni, D., Saccomani, V., and Piovan, E. (2017). Aberrant Signaling Pathways in T-Cell Acute Lymphoblastic Leukemia. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18091904"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.7150\/jca.21725","article-title":"T-cell Acute Lymphoblastic Leukemia Cells Display Activation of Different Survival Pathways","volume":"8","author":"Moharram","year":"2017","journal-title":"J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.canlet.2017.07.019","article-title":"Efficacy of the CDK inhibitor dinaciclib in vitro and in vivo in T-cell acute lymphoblastic leukemia","volume":"405","author":"Moharram","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13148-018-0516-x","article-title":"Acute leukemia cells resistant to PI3K\/mTOR inhibition display upregulation of P2RY14 expression","volume":"10","author":"Shah","year":"2018","journal-title":"Clin. Epigenetics"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-020-00905-2","article-title":"Evolving therapy of adult acute lymphoblastic leukemia: State-of-the-art treatment and future directions","volume":"13","author":"Samra","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11899-019-00501-3","article-title":"Relapsed T Cell ALL: Current Approaches and New Directions","volume":"14","author":"McMahon","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","article-title":"T cell receptor (TCR) signaling in health and disease","volume":"6","author":"Shah","year":"2021","journal-title":"Signal Transduct. Target"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4049\/jimmunol.151.1.83","article-title":"bcl-2 proto-oncogene expression during human T cell development. Evidence for biphasic regulation","volume":"151","author":"Ding","year":"1993","journal-title":"J. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.4049\/jimmunol.151.5.2546","article-title":"Expression of the Bcl-2 protein in murine and human thymocytes and in peripheral T lymphocytes","volume":"151","author":"Veis","year":"1993","journal-title":"J. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"ref_12","first-page":"456","article-title":"Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome","volume":"10","author":"Robertson","year":"1996","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-15-1191","article-title":"Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma","volume":"22","author":"Klanova","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.1158\/1078-0432.CCR-07-1598","article-title":"BCL-2 family proteins: Critical checkpoints of apoptotic cell death","volume":"13","author":"Danial","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/febs.14186","article-title":"Bax, Bak and beyond\u2014Mitochondrial performance in apoptosis","volume":"285","year":"2018","journal-title":"FEBS J."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Or, C.R., Huang, C.W., Chang, C.C., Lai, Y.C., Chen, Y.J., and Chang, C.C. (2020). Obatoclax, a Pan-BCL-2 Inhibitor, Downregulates Survivin to Induce Apoptosis in Human Colorectal Carcinoma Cells Via Suppressing WNT\/beta-catenin Signaling. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051773"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1038\/s41418-018-0244-y","article-title":"By reducing global mRNA translation in several ways, 2-deoxyglucose lowers MCL-1 protein and sensitizes hemopoietic tumor cells to BH3 mimetic ABT737","volume":"26","author":"Tailler","year":"2019","journal-title":"Cell Death Differ."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1021\/jm1001265","article-title":"BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma\/leukemia-2 (Bcl-2) family proteins","volume":"53","author":"Wei","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","article-title":"BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines","volume":"34","author":"Merino","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41419-020-03144-y","article-title":"Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance","volume":"11","author":"Kapoor","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3389\/fcell.2020.00354","article-title":"The Senolytic Drug Navitoclax (ABT-263) Causes Trabecular Bone Loss and Impaired Osteoprogenitor Function in Aged Mice","volume":"8","author":"Sharma","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Bohler, S., Afreen, S., Fernandez-Orth, J., Demmerath, E.M., Molnar, C., Wu, Y., Weiss, J.M., Mittapalli, V.R., Konstantinidis, L., and Schmal, H. (2020). Inhibition of the anti-apoptotic protein MCL-1 severely suppresses human hematopoiesis. Haematologica, Online ahead of print.","DOI":"10.3324\/haematol.2020.252130"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1158\/0008-5472.CAN-17-3024","article-title":"Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells","volume":"78","author":"Rahmani","year":"2018","journal-title":"Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","article-title":"Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells","volume":"22","author":"Niu","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3389\/fonc.2018.00458","article-title":"Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?","volume":"8","author":"Leverson","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Klanova, M., and Klener, P. (2020). BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas. Cancers, 12.","DOI":"10.3390\/cancers12040938"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1038\/sj.onc.1206792","article-title":"Phosphorylation of Bim-EL by Erk1\/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function","volume":"22","author":"Luciano","year":"2003","journal-title":"Oncogene"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1158\/2159-8290.CD-12-0504","article-title":"TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia","volume":"3","author":"Sanda","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/sj.cdd.4400724","article-title":"Cytokine regulation of apoptosis and Bcl-2 expression in lymphocytes of patients with systemic lupus erythematosus","volume":"7","author":"Graninger","year":"2000","journal-title":"Cell Death Differ."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1126\/science.3874430","article-title":"Involvement of the bcl-2 gene in human follicular lymphoma","volume":"228","author":"Tsujimoto","year":"1985","journal-title":"Science"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1172\/JCI63186","article-title":"Pathogenesis of follicular lymphoma","volume":"122","author":"Kridel","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Damerau, A., Gaber, T., Ohrndorf, S., and Hoff, P. (2020). JAK\/STAT Activation: A General Mechanism for Bone Development, Homeostasis, and Regeneration. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239004"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1006\/bbrc.1996.0674","article-title":"Interleukin 3 activates not only JAK2 and STAT5, but also Tyk2, STAT1, and STAT3","volume":"221","author":"Nagata","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8705","DOI":"10.1073\/pnas.92.19.8705","article-title":"Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15","volume":"92","author":"Johnston","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"eaav1080","DOI":"10.1126\/sciimmunol.aav1080","article-title":"IL-23 and IL-2 activation of STAT5 is required for optimal IL-22 production in ILC3s during colitis","volume":"5","author":"Bauche","year":"2020","journal-title":"Sci. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"101354","DOI":"10.1016\/j.tranon.2022.101354","article-title":"Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD\/D835 mutant AML","volume":"18","author":"Yamatani","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1182\/blood-2008-12-196055","article-title":"FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation","volume":"114","author":"Yoshimoto","year":"2009","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1038\/sj.onc.1202796","article-title":"IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line","volume":"18","author":"Dumon","year":"1999","journal-title":"Oncogene"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","article-title":"FMS-like Tyrosine Kinase 3\/FLT3: From Basic Science to Clinical Implications","volume":"99","author":"Kazi","year":"2019","journal-title":"Physiol. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5416923","DOI":"10.1155\/2018\/5416923","article-title":"Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment","volume":"2018","author":"Phi","year":"2018","journal-title":"Stem Cells Int."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Yang, W., Kim, D., Kim, D.K., Choi, K.U., Suh, D.S., and Kim, J.H. (2021). Therapeutic Strategies for Targeting Ovarian Cancer Stem Cells. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22105059"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Barman, S., Fatima, I., Singh, A.B., and Dhawan, P. (2021). Pancreatic Cancer and Therapy: Role and Regulation of Cancer Stem Cells. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094765"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Kazi, J.U. (2020). Mechanisms of Anticancer Therapy Resistance: The Role of Cancer Stem Cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239006"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood.2020006343","article-title":"CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues","volume":"138","author":"Yu","year":"2021","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1182\/blood-2018-02-833582","article-title":"CD44 is a RAS\/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis","volume":"132","author":"Mueller","year":"2018","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"20778","DOI":"10.1073\/pnas.1019452108","article-title":"Notch1 regulates the expression of the multidrug resistance gene ABCC1\/MRP1 in cultured cancer cells","volume":"108","author":"Cho","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1038\/leu.2017.136","article-title":"JAK\/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias","volume":"31","author":"Meyer","year":"2017","journal-title":"Leukemia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41525-019-0082-y","article-title":"Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation","volume":"4","author":"Chougule","year":"2019","journal-title":"NPJ Genom. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1038\/onc.2016.41","article-title":"Aberrant activation of the PI3K\/mTOR pathway promotes resistance to sorafenib in AML","volume":"35","author":"Lindblad","year":"2016","journal-title":"Oncogene"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/5\/5004\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:48:28Z","timestamp":1760122108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/5\/5004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,5]]},"references-count":54,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["ijms24055004"],"URL":"https:\/\/doi.org\/10.3390\/ijms24055004","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,5]]}}}